Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
Stable expression over 15 generations with rapid cell line development in just 3 months. Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
Predicted to enable monooxygenase activity. Acts upstream of or within cellular response to xenobiotic stimulus. Predicted to be located in endoplasmic reticulum membrane. Predicted to be active in intracellular membrane-bounded organelle. Is expressed in several structures, including digestive system; pectoral fin bud; pericardial region; tail bud; and vasculature. Human ortholog(s) of this gene implicated in several diseases, including autoimmune disease (multiple); diabetes mellitus (multiple); gastrointestinal system cancer (multiple); hematologic cancer (multiple); and lung disease (multiple). Orthologous to human CYP1A1 (cytochrome P450 family 1 subfamily A member 1) and CYP1A2 (cytochrome P450 family 1 subfamily A member 2). [provided by Alliance of Genome Resources, Feb 2025]